ATE461701T1 - Mikronisiertes tanaproget und zusammensetzungen damit - Google Patents
Mikronisiertes tanaproget und zusammensetzungen damitInfo
- Publication number
- ATE461701T1 ATE461701T1 AT06751636T AT06751636T ATE461701T1 AT E461701 T1 ATE461701 T1 AT E461701T1 AT 06751636 T AT06751636 T AT 06751636T AT 06751636 T AT06751636 T AT 06751636T AT E461701 T1 ATE461701 T1 AT E461701T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- magnesium stearate
- microcrystalline cellulose
- croscarmellose sodium
- contain microcrystalline
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 title abstract 2
- 229950001471 tanaproget Drugs 0.000 title abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 4
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 2
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 2
- 235000019359 magnesium stearate Nutrition 0.000 abstract 2
- 229940057948 magnesium stearate Drugs 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 229960004977 anhydrous lactose Drugs 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 230000002632 myometrial effect Effects 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fertilizers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67555105P | 2005-04-28 | 2005-04-28 | |
| PCT/US2006/016020 WO2006116596A2 (en) | 2005-04-28 | 2006-04-26 | Micronized tanaproget and compostions containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE461701T1 true ATE461701T1 (de) | 2010-04-15 |
Family
ID=37027926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06751636T ATE461701T1 (de) | 2005-04-28 | 2006-04-26 | Mikronisiertes tanaproget und zusammensetzungen damit |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20060246128A1 (de) |
| EP (1) | EP1877059B8 (de) |
| JP (3) | JP5149160B2 (de) |
| CN (1) | CN101166533A (de) |
| AT (1) | ATE461701T1 (de) |
| AU (1) | AU2006239284C1 (de) |
| BR (1) | BRPI0610431A2 (de) |
| CA (1) | CA2603594C (de) |
| CY (1) | CY1110017T1 (de) |
| DE (1) | DE602006013114D1 (de) |
| DK (1) | DK1877059T3 (de) |
| ES (1) | ES2340518T3 (de) |
| MX (1) | MX2007013467A (de) |
| PL (1) | PL1877059T3 (de) |
| PT (1) | PT1877059E (de) |
| SI (1) | SI1877059T1 (de) |
| WO (1) | WO2006116596A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0203332A3 (en) * | 1999-05-04 | 2004-12-28 | Wyeth Corp | Cyclothiocarbamate derivatives, their use as progesterone receptor modulators and pharmaceutical compositions containing them |
| BRPI0610431A2 (pt) * | 2005-04-28 | 2012-10-23 | Wyeth Corp | composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico |
| DE602006012972D1 (de) * | 2005-04-28 | 2010-04-29 | Wyeth Corp | Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung |
| MX2007013469A (es) * | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| JP5149161B2 (ja) * | 2005-04-28 | 2013-02-20 | ワイス・エルエルシー | ミクロ化タナプロゲットを含む組成物 |
| TW200716137A (en) | 2005-06-09 | 2007-05-01 | Wyeth Corp | Tanaproget compositions containing ethinyl estradiol |
| EA201070715A1 (ru) | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
| US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| AU2010239080B2 (en) | 2009-04-24 | 2014-08-28 | Iceutica Pty Ltd | A novel formulation of diclofenac |
| US9326997B2 (en) | 2012-09-24 | 2016-05-03 | Ahlam E. Elakkad | Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea |
| US20160310457A1 (en) * | 2013-12-12 | 2016-10-27 | Almirall, S.A. | Pharmaceutical compositions comprising dimethyl fumarate |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| PL3892302T3 (pl) * | 2015-04-06 | 2024-03-11 | Janssen Pharmaceutica Nv | Kompozycje zawierające ibrutynib |
| WO2017003951A1 (en) * | 2015-06-29 | 2017-01-05 | Phloronol, Inc. | Solid pharmaceutical compositions of brown algae |
| MA49448A (fr) | 2017-06-23 | 2020-04-29 | Almirall Sa | Compositions pharmaceutiques contenant du fumarate de diméthyle |
| CN117180214B (zh) * | 2023-10-26 | 2024-07-12 | 杭州和泽坤元药业有限公司 | 一种地屈孕酮片剂组合物及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2006A (en) * | 1841-03-16 | Clamp for crimping leather | ||
| US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
| US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
| US6423699B1 (en) | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
| HUP0203332A3 (en) * | 1999-05-04 | 2004-12-28 | Wyeth Corp | Cyclothiocarbamate derivatives, their use as progesterone receptor modulators and pharmaceutical compositions containing them |
| US6544553B1 (en) * | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| US7056906B2 (en) * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US6962908B2 (en) | 2001-12-21 | 2005-11-08 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| CN1662241A (zh) * | 2002-06-25 | 2005-08-31 | 惠氏公司 | 环硫代氨基甲酸酯衍生物在治疗与激素有关的病症中的用途 |
| CN1665510A (zh) | 2002-06-25 | 2005-09-07 | 惠氏公司 | 作为pr调节剂的环硫代氨基甲酸酯衍生物的衍生物和其用于治疗皮肤病的用途 |
| US8404272B2 (en) * | 2003-06-26 | 2013-03-26 | Poly-Med, Inc. | Fiber-reinforced composite rings for intravaginal controlled drug delivery |
| CN1946716B (zh) * | 2004-04-27 | 2011-12-21 | 惠氏公司 | 含有氰基吡咯的环状氨基甲酸酯和硫代氨基甲酸酯联芳基以及其制备方法 |
| CA2563063C (en) | 2004-04-27 | 2014-06-03 | Wyeth | Purification of progesterone receptor modulators |
| AR049631A1 (es) | 2004-04-27 | 2006-08-23 | Wyeth Corp | Proceso de acoplamiento para la generacion de derivados reactivos de pirrol -2- carbonitrilo n- sustituidos con contenido de boro para producir biarilos |
| US20060009428A1 (en) * | 2004-07-07 | 2006-01-12 | Wyeth | Cyclic progestin regimens and kits |
| GT200500183A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| CA2575737C (en) * | 2004-08-13 | 2013-09-24 | Wyeth | Tanaproget derivatives, metabolites, and uses thereof |
| CA2575803A1 (en) | 2004-08-20 | 2006-03-23 | Wyeth | Progesterone receptor structure |
| DE602006012972D1 (de) * | 2005-04-28 | 2010-04-29 | Wyeth Corp | Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung |
| PE20061322A1 (es) | 2005-04-28 | 2006-12-28 | Wyeth Corp | Forma purificada de tanaproget |
| JP5149161B2 (ja) * | 2005-04-28 | 2013-02-20 | ワイス・エルエルシー | ミクロ化タナプロゲットを含む組成物 |
| BRPI0610431A2 (pt) | 2005-04-28 | 2012-10-23 | Wyeth Corp | composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico |
| MX2007013469A (es) | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| TW200716137A (en) | 2005-06-09 | 2007-05-01 | Wyeth Corp | Tanaproget compositions containing ethinyl estradiol |
-
2006
- 2006-04-26 BR BRPI0610431-2A patent/BRPI0610431A2/pt not_active IP Right Cessation
- 2006-04-26 WO PCT/US2006/016020 patent/WO2006116596A2/en not_active Ceased
- 2006-04-26 CA CA2603594A patent/CA2603594C/en not_active Expired - Fee Related
- 2006-04-26 PT PT06751636T patent/PT1877059E/pt unknown
- 2006-04-26 ES ES06751636T patent/ES2340518T3/es not_active Expired - Lifetime
- 2006-04-26 EP EP06751636A patent/EP1877059B8/de not_active Expired - Lifetime
- 2006-04-26 DE DE602006013114T patent/DE602006013114D1/de not_active Expired - Lifetime
- 2006-04-26 PL PL06751636T patent/PL1877059T3/pl unknown
- 2006-04-26 DK DK06751636.9T patent/DK1877059T3/da active
- 2006-04-26 JP JP2008509116A patent/JP5149160B2/ja not_active Expired - Fee Related
- 2006-04-26 US US11/412,022 patent/US20060246128A1/en not_active Abandoned
- 2006-04-26 CN CNA2006800142307A patent/CN101166533A/zh active Pending
- 2006-04-26 AU AU2006239284A patent/AU2006239284C1/en not_active Ceased
- 2006-04-26 AT AT06751636T patent/ATE461701T1/de active
- 2006-04-26 MX MX2007013467A patent/MX2007013467A/es active IP Right Grant
- 2006-04-26 SI SI200630648T patent/SI1877059T1/sl unknown
-
2010
- 2010-05-05 CY CY20101100393T patent/CY1110017T1/el unknown
- 2010-12-22 US US12/975,444 patent/US8513240B2/en not_active Expired - Fee Related
-
2012
- 2012-07-31 JP JP2012169827A patent/JP2012255000A/ja active Pending
-
2013
- 2013-07-23 US US13/948,762 patent/US20130337058A1/en not_active Abandoned
-
2014
- 2014-05-26 JP JP2014108570A patent/JP2014205684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5149160B2 (ja) | 2013-02-20 |
| CA2603594A1 (en) | 2006-11-02 |
| CY1110017T1 (el) | 2015-01-14 |
| US8513240B2 (en) | 2013-08-20 |
| WO2006116596A2 (en) | 2006-11-02 |
| JP2008539262A (ja) | 2008-11-13 |
| JP2012255000A (ja) | 2012-12-27 |
| DE602006013114D1 (de) | 2010-05-06 |
| EP1877059B8 (de) | 2010-05-19 |
| US20110091539A1 (en) | 2011-04-21 |
| WO2006116596A3 (en) | 2006-12-14 |
| DK1877059T3 (da) | 2010-05-31 |
| AU2006239284A1 (en) | 2006-11-02 |
| CA2603594C (en) | 2013-11-05 |
| ES2340518T3 (es) | 2010-06-04 |
| CN101166533A (zh) | 2008-04-23 |
| EP1877059B1 (de) | 2010-03-24 |
| JP2014205684A (ja) | 2014-10-30 |
| AU2006239284B2 (en) | 2011-03-31 |
| US20130337058A1 (en) | 2013-12-19 |
| PT1877059E (pt) | 2010-05-04 |
| MX2007013467A (es) | 2008-01-21 |
| US20060246128A1 (en) | 2006-11-02 |
| BRPI0610431A2 (pt) | 2012-10-23 |
| SI1877059T1 (sl) | 2010-07-30 |
| AU2006239284C1 (en) | 2011-07-28 |
| PL1877059T3 (pl) | 2010-07-30 |
| EP1877059A2 (de) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110017T1 (el) | Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην | |
| TW200716129A (en) | Micronized tanaproget, compositions, and methods of preparing the same | |
| TW200716621A (en) | Polymorph form II of tanaproget | |
| Engel et al. | Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone | |
| DK1874278T3 (da) | Sammensætninger indeholdende mikroniseret tanaproget | |
| PH12012501129A1 (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| CY1121926T1 (el) | (11.βητα., 17.βητα.)-17-υδροξυ-11-[4(μεθυλοσουλφονυλο)φαινυλο]-17-(πενταφθορομεθυλο)οιστρα-4,9-διεν-3-ονη για την αγωγη παθησεων | |
| CY1106610T1 (el) | Μεθοδος για την προληψη ή την θεραπευτικη αντιμετωπιση καλοηθων γυναικολογικων διαταραχων | |
| TW200731969A (en) | Use of progesterone receptor modulators | |
| RU2016119135A (ru) | Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения | |
| MXPA04004956A (es) | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. | |
| ATE515493T1 (de) | Mercaptophenylnaphthylmethan-derivate und deren herstellung | |
| EA201491344A1 (ru) | Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона | |
| NO20031740D0 (no) | Anvendelse av antiprogestiner for profylakse og behandling av hormonavhengige sykdommer | |
| CA2738993C (en) | Pharmaceutical composition utilising combinations of variants of the gonadotropin-releasing hormone (gnrh) as immunogen | |
| NZ515353A (en) | Cyclothiocarbamate derivatives as progesterone receptor modulators | |
| DE602005019905D1 (de) | -modulatoren | |
| DE60013798D1 (de) | Empfängnisverhütende zusammensetzungen die progestagen und progesteronantagonisten enthalten | |
| CY1109919T1 (el) | Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης | |
| MX2009009515A (es) | Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona. | |
| NO20006479L (no) | Tienopyridinforbindelser, deres fremstilling og anvendelse | |
| ATE512985T1 (de) | Diagnostische und therapeutische anwendungen von löslichem lhcgr-protein | |
| DE60122575D1 (de) | 7-HETEROCYCLYL-SUBSTITUIERTE CHINOLIN- UND THIENOi2,3-BöPYRIDIN-DERIVATE ALS ANTAGONISTEN DES GONADOTROPIN-FREISETZENDEN HORMONS | |
| NO20055493L (no) | 8β-vinyl-11β-(w-substituerte)alkyl-ostra-1,3,5(10)-triener | |
| 黃其民 et al. | Surgical Resection Combined with Systemic Imatinib Therapy for the Treatment of Advanced Gastrointestinal Stromal Tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1877059 Country of ref document: EP |